In other healthcare policy news, the head of the NHS unveiled a new five-year plan for our health service, but highlighted the need for further government investment, according to the BBC.
A drug we helped develop edged closer to getting a European license. Olaparib – a type of drug known as a PARP inhibitor – has shown promise in treating women whose ovarian cancer is caused by a faulty BRCA gene. We blogged about the announcement; here’s Reuters’ take.
We announced a new funding scheme to develop so-called ‘biotherapeutics’ – cancer drugs made from biological molecules rather than synthetic chemicals. Read more in this blog post.
Cancer Research UK researchers at University College London made a compelling discovery about how lymph nodes swell during infection – something that sheds new light on how the immune system works. Our blog post has some amazing images – read it here.
The BBC reported on the announcement of a new £110m ‘Precision Cancer Medicine Institute’ in Oxford.
US researchers announced promising early results for a new experimental cancer drug, which can shrink lung tumours in mice. We covered the story on our news feed, as did the Mirror.
It’s not a breakthrough (sorry STV), but it is really interesting – researchers in Dundee (part-funded by Cancer Research UK) discover another piece in the elaborate jigsaw puzzle of how DNA is replicated when cells multiply.
“The war on cancer is stalling” because pharmaceutical companies only make drugs for profit, according to comments by a UK researcher published in the Daily Mail.
This fascinating article in Nature News looked at how cancer cells can shed tiny particles of a molecule called RNA, that can affect their neighbours.
A small study involving mice fed different diets and exposed to UV rays led to alarmist and incorrect headlines such as “Sunlight is key to diabetes fight”. This is unhelpful, dangerous and inaccurate. We looked at the research in this blog post.